<DOC>
	<DOCNO>NCT00798070</DOCNO>
	<brief_summary>This adjuvant , open , prospective , randomize study compare : A . Individually tailor two weekly dose epirubicin + cyclophosphamide follow three week break followed biweekly tailor docetaxel ( dtEC→dtT ) give every second week , B . Fixed dose three weekly epirubicin , cyclophosphamide 5-fluorouracil , follow fix dose three weekly docetaxel ( FEC→T ) . Patients primary node-positive high risk lymph node negative breast cancer eligible study . The primary objective phase 3 study compare breast cancer relapse-free survival ( BCRFS ) dtEC→dtT FE100C→T . To detect five-year BCRFS difference 0.710 0.790 1000 patient per arm need . They recruit four year follow another two year breast cancer event . Secondary objective compare 1 . Distant disease-free survival ( DDFS ) 2 . Event-free survival 3 . Overall survival 4 . Health-related quality life toxicity analyse accord CTC 5 . Outcome relation tumour biological factor polymorphism pattern 1 . RFS relation Sorlie class use immunohistochemical marker and/or gene expression profile compare A v B arm 2 . RFS receptor positive disease ( analyzed local laboratory describe CRFs also analyze continuous variable ) comparison A- B- arm . 3 . RFS high low proliferation , respectively , ( analyzed local laboratory describe CRFs also analyze continuous variable , centrally analyze ) , comparison A- B-arms . 4 . RFS relation HER-2/neu status ( analyzed local laboratory describe CRFs ) primary cancer comparison A- B-arms analyze whether trastuzumab give sequence concurrently . 5 . RFS analyzed relation molecular marker ( e.g . gene expression profiling/ sequence ) primary cancer SNPs signatures normal DNA ( related toxicity EC/FEC docetaxel component , respectively , give dose level outcome relation factor relation QoL ) outcome per arm . 6 . RFS analyze relation tumour associate lymphocytes Y-box bind protein comparison A- B-arms . Tumour tissue obtain stored study prognostication therapy prediction . Last patient randomize September 2011 .</brief_summary>
	<brief_title>Panther : A Study Comparing Biweekly Tailored EC-T Versus Three Weekly FEC-T Breast Cancer Patients</brief_title>
	<detailed_description>Are describe head `` Outcome measure ''</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histological proven invasive primary breast cancer , least 5 ( recommend 10 ) remove axillary lymph node OR negative sentinel node biopsy performed node negative cohort . Interval definitive surgery include axillary lymph node dissection registration must less 60 day . Paraffin block primary tumour must retain ( mandatory Austrian site ) . Frozen tumour tissue strongly recommend store . Receptor negative positive tumour 1 positive axillary lymph node ( 0.2 mm ) OR axillary node negative breast cancer primary tumour large 20 mm receptor negative ( Er Pgr receptor content ) Elston grade III . In Germany high risk node negative breast cancer patient eligible label docetaxel include nodenegative disease . A primary breast cancer patient 35 year younger consider suitable adjuvant chemotherapy ( may receptor negative positive , HER2/neu negative positive , without axillary lymph node metastasis ) . Macroscopically microscopically free margin radical surgery ( cancer cell border resection ) . No proven distant metastasis ( negative chest/pulmonary Xray , bone scintigram ( clinical sign skeletal metastasis elevate ALP ) supplement normal conventional Xray hot spot , normal liver function test haematological function test ; abnormal value , CT ultrasound liver , patient include metastasis demonstrate . Female age 1865 . Ambulant patient ( ECOG 1 less ) . No major cardiovascular morbidity NYHA I II . ( Appendix 3 ) . Written inform consent accord local ethic committee requirement . Patients childbearing potential negative pregnancy test within seven day registration . ( In Austria , pregnancy test repeat monthly treatment phase ) . Previous neoadjuvant treatment . Nonradical surgery ( histopathological positive margin ) . Proven distant metastasis . Pregnancy lactation . Other serious medical condition . Previous concurrent malignancy sit , except basal cell carcinoma and/or squamous cell carcinoma situ skin cervix . Patients previous breast cancer ( invasive and/or ductal carcinoma situ ) breast without locoregional ( large lung volume ) radiotherapy , without objective finding relapse , &gt; 5 year since diagnosis include . Abnormal laboratory value preclude possibility safely deliver use cytotoxic agent study . Hypersensitivity drug formulate polysorbate 80 . Peripheral neuropathy grade ≥2 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lymph node positive high risk lymph node negative breast</keyword>
	<keyword>cancer</keyword>
</DOC>